{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:08:22Z","timestamp":1767971302448,"version":"3.49.0"},"reference-count":133,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>(1) Background: Second-generation integrase strand transfer inhibitors (INSTIs) are now the preferred first-line therapies for human immunodeficiency virus (HIV). However, concerns regarding their side effects, such as weight gain and metabolic disturbances, have emerged. This scoping review aims to assess the effects of INSTIs on the gut microbiota, with a focus on differences between agents and their clinical implications. (2) Methods: A scoping review was conducted using PubMed, Web of Science, and Embase, with reports collected following PRISMA for Scoping Reviews (PRISMA-ScR). (3) Results: The majority of available evidence focused on dolutegravir, which demonstrated beneficial effects on microbiota diversity and composition. However, factors such as younger age, lower CD4+ counts, and extreme BMI were associated with proinflammatory changes. Limited data on bictegravir also suggested favorable alterations in the gut microbiota. Raltegravir, a first-generation INSTI, was associated with improvements in alpha diversity and microbial composition, although these changes were not consistently beneficial. Moreover, associated changes in inflammatory and microbial translocation markers suggested unfavorable alterations. (4) Conclusions: Based on the evidence mapped, second-generation INSTIs may generally induce favorable changes in the gut microbiota. However, further research is needed to explore the clinical implications of these microbiota alterations, particularly in specific patient groups.<\/jats:p>","DOI":"10.3390\/ijms26136366","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:10:26Z","timestamp":1751436626000},"page":"6366","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mapping the Gut Microbiota Composition in the Context of Raltegravir, Dolutegravir, and Bictegravir\u2014A Scoping Review"],"prefix":"10.3390","volume":"26","author":[{"given":"Zs\u00f3fia","family":"G\u00e1sp\u00e1r","sequence":"first","affiliation":[{"name":"National Institute of Haematology and Infectious Diseases, Central Hospital of Southern Pest, H-1097 Budapest, Hungary"},{"name":"Doctoral School of Clinical Medicine, Semmelweis University, H-1085 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Botond","family":"Lakatos","sequence":"additional","affiliation":[{"name":"National Institute of Haematology and Infectious Diseases, Central Hospital of Southern Pest, H-1097 Budapest, Hungary"},{"name":"Doctoral School of Clinical Medicine, Semmelweis University, H-1085 Budapest, Hungary"},{"name":"Departmental Group of Infectious Diseases, Department of Internal Medicine and Hematology, Semmelweis University, H-1088 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0253-7184.132399","article-title":"Initiation of antiretroviral therapy","volume":"35","author":"Pandhi","year":"2014","journal-title":"Indian J. Sex. Transm. Dis. AIDS"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bcp.12403","article-title":"The evolution of three decades of antiretroviral therapy: Challenges, triumphs and the promise of the future","volume":"79","author":"Tseng","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_3","unstructured":"Eggleton, J.S., and Nagalli, S. (2025). Highly Active Antiretroviral Therapy (HAART). StatPearls, StatPearls Publishing."},{"key":"ref_4","unstructured":"EACS (2025, February 15). EACS Guidelines v12.0. Available online: https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf."},{"key":"ref_5","unstructured":"Clinicalinfo.HIV.gov (2025, February 15). What to Start: Initial Combination Antiretroviral Regimens for People with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/what-start-initial-combination."},{"key":"ref_6","unstructured":"LiverTox (2012). Protease Inhibitors (HIV). LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Weber, I.T., Wang, Y.F., and Harrison, R.W. (2021). HIV Protease: Historical Perspective and Current Research. Viruses, 13.","DOI":"10.3390\/v13050839"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2022.0502","article-title":"Advances in the treatment and prevention of HIV: What you need to know","volume":"84","author":"Colloty","year":"2023","journal-title":"Br. J. Hosp. Med."},{"key":"ref_9","unstructured":"Kemnic, T.R., and Gulick, P.G. (2025). HIV Antiretroviral Therapy. StatPearls, National Library of Medicine."},{"key":"ref_10","unstructured":"NIH (2025, June 27). The HIV Life Cycle, Available online: https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/hiv-life-cycle."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"106403","DOI":"10.1016\/j.ijantimicag.2021.106403","article-title":"Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV","volume":"58","author":"Lee","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/hiv.13008","article-title":"The effect of protease inhibitor-based dual antiretroviral regimens on CD4\/CD8 ratio during the first year of therapy in ART-naive patients with HIV-infection","volume":"22","author":"Figueroa","year":"2021","journal-title":"HIV Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Vanangamudi, M., Palaniappan, S., Kathiravan, M.K., and Namasivayam, V. (2023). Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). Viruses, 15.","DOI":"10.3390\/v15101992"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.coph.2020.10.009","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs): A brief overview of clinically approved drugs and combination regimens","volume":"54","author":"Vanangamudi","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.idc.2019.05.003","article-title":"Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?","volume":"33","author":"Kelly","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-022-00608-1","article-title":"A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/phar.2246","article-title":"Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?","volume":"39","author":"Brooks","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: Final 5-year results from STARTMRK","volume":"63","author":"Rockstroh","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M14-1084","article-title":"Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: A randomized, controlled equivalence trial","volume":"161","author":"Lennox","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Smith, S.J., Zhao, X.Z., Passos, D.O., Lyumkis, D., Burke, T.R., and Hughes, S.H. (2021). Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. Viruses, 13.","DOI":"10.3390\/v13020205"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"ref_25","unstructured":"WHO (2025, February 17). WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations. Available online: https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"ref_27","unstructured":"LiverTox (2012). Bictegravir. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-018-1010-7","article-title":"Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Review in HIV-1 Infection","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-020-01457-y","article-title":"Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?","volume":"81","author":"Shah","year":"2021","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14787210.2022.2081153","article-title":"Cabotegravir\/Rilpivirine: The last FDA-approved drug to treat HIV","volume":"20","author":"Taki","year":"2022","journal-title":"Expert. Rev. Anti-Infect. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/QCO.0000000000000695","article-title":"Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy","volume":"34","author":"Shah","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: A randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/QAD.0000000000003865","article-title":"Switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir-based therapy","volume":"38","author":"Orkin","year":"2024","journal-title":"AIDS"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2025.01.013","article-title":"Comparative effectiveness of bictegravir versus dolutegravir, raltegravir, and efavirenz-based antiretroviral therapy among treatment-naive individuals with HIV","volume":"133","author":"Nunez","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s40121-023-00879-x","article-title":"Bictegravir\/Emtricitabine\/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study","volume":"12","author":"Gan","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G.A.D., Gasbarrini, A., and Mele, M.C. (2019). What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms, 7.","DOI":"10.3390\/microorganisms7010014"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Al Bander, Z., Nitert, M.D., Mousa, A., and Naderpoor, N. (2020). The Gut Microbiota and Inflammation: An Overview. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17207618"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/COH.0000000000000429","article-title":"Altered gut microbiome composition in HIV infection: Causes, effects and potential intervention","volume":"13","author":"Bandera","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","article-title":"Role of the normal gut microbiota","volume":"21","author":"Jandhyala","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17562848221134396","DOI":"10.1177\/17562848221134396","article-title":"The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection","volume":"15","author":"Seekatz","year":"2022","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kers, J.G., and Saccenti, E. (2021). The Power of Microbiome Studies: Some Considerations on Which Alpha and Beta Metrics to Use and How to Report Results. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.796025"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lazzaro, A., Innocenti, G.P., Santinelli, L., Pinacchio, C., De Girolamo, G., Vassalini, P., Fanello, G., Mastroianni, C.M., Ceccarelli, G., and d\u2019Ettorre, G. (2021). Antiretroviral Therapy Dampens Mucosal CD4(+) T Lamina Propria Lymphocytes Immune Activation in Long-Term Treated People Living with HIV-1. Microorganisms, 9.","DOI":"10.3390\/microorganisms9081624"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pan, Z., Wu, N., and Jin, C. (2023). Intestinal Microbiota Dysbiosis Promotes Mucosal Barrier Damage and Immune Injury in HIV-Infected Patients. Can. J. Infect. Dis. Med. Microbiol., 2023.","DOI":"10.1155\/2023\/3080969"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1089\/aid.2019.0282","article-title":"Review on the Alteration of Gut Microbiota: The Role of HIV Infection and Old Age","volume":"36","author":"Ashuro","year":"2020","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/clinpract14030066","article-title":"Alterations in the Gut Microbiome Composition of People Living with HIV in the Asia-Pacific Region: A Systematic Review","volume":"14","author":"Salvador","year":"2024","journal-title":"Clin. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11904-019-00441-w","article-title":"HIV and the Gut Microbiota: Composition, Consequences, and Avenues for Amelioration","volume":"16","author":"Somsouk","year":"2019","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Satish, S., Abu, Y., Gomez, D., Kumar Dutta, R., and Roy, S. (2023). HIV, opioid use, and alterations to the gut microbiome: Elucidating independent and synergistic effects. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1156862"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41467-023-44566-4","article-title":"HIV-associated gut microbial alterations are dependent on host and geographic context","volume":"15","author":"Rocafort","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Salazar, N., Arboleya, S., Fernandez-Navarro, T., de Los Reyes-Gavilan, C.G., Gonzalez, S., and Gueimonde, M. (2019). Age-Associated Changes in Gut Microbiota and Dietary Components Related with the Immune System in Adulthood and Old Age: A Cross-Sectional Study. Nutrients, 11.","DOI":"10.3390\/nu11081765"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tr\u00f8seid, M., Nielsen, S.D., and Vujkovic-Cvijin, I. (2024). Gut microbiome and cardiometabolic comorbidities in people living with HIV. Microbiome, 12.","DOI":"10.1186\/s40168-024-01815-y"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Valeri, F., and Endres, K. (2021). How biological sex of the host shapes its gut microbiota. Front. Neuroendocrinol., 61.","DOI":"10.1016\/j.yfrne.2021.100912"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Mac Cann, R., Newman, E., Devane, D., Sabin, C., Cotter, A.G., Landay, A., O\u2019Toole, P.W., and Mallon, P.W. (2024). HIV, the gut microbiome and clinical outcomes, a systematic review. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0308859"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ishizaka, A., Koga, M., Mizutani, T., Parbie, P.K., Prawisuda, D., Yusa, N., Sedohara, A., Kikuchi, T., Ikeuchi, K., and Adachi, E. (2021). Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation. Microbiol. Spectr., 9.","DOI":"10.1128\/Spectrum.00708-21"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"113336","DOI":"10.1016\/j.celrep.2023.113336","article-title":"Impaired gut microbiota-mediated short-chain fatty acid production precedes morbidity and mortality in people with HIV","volume":"42","author":"Sereti","year":"2023","journal-title":"Cell Rep."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Hern\u00e1ndez, L.A., Ruiz-Brise\u00f1o, M.D.R., S\u00e1nchez-Reyes, K., Alvarez-Zavala, M., Vega-Maga\u00f1a, N., L\u00f3pez-I\u00f1iguez, A., D\u00edaz-Ramos, J.A., Mart\u00ednez-Ayala, P., Soria-Rodriguez, R.A., and Ramos-Solano, M. (2019). Alterations in bacterial communities, SCFA and biomarkers in an elderly HIV-positive and HIV-negative population in western Mexico. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3867-9"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Fulcher, J.A., Li, F., Tobin, N.H., Zabih, S., Elliott, J., Clark, J.L., D\u2019Aquila, R., Mustanski, B., Kipke, M.D., and Shoptaw, S. (2022). Gut dysbiosis and inflammatory blood markers precede HIV with limited changes after early seroconversion. EBioMedicine, 84.","DOI":"10.1016\/j.ebiom.2022.104286"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.20411\/pai.v10i1.746","article-title":"Inflammation and Microbial Translocation Correlate with Reduced MAIT Cells in People with HIV","volume":"10","author":"Ryu","year":"2024","journal-title":"Pathog. Immun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/JLB.2MR0220-549R","article-title":"ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis","volume":"108","author":"Bui","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ouyang, J., Yan, J., Zhou, X., Isnard, S., Harypursat, V., Cui, H., Routy, J.P., and Chen, Y. (2023). Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1173956"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/imr.12064","article-title":"Immune restoration after antiretroviral therapy: The pitfalls of hasty or incomplete repairs","volume":"254","author":"Wilson","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Gaspar, Z., Nagavci, B., Szabo, B.G., and Lakatos, B. (2024). Gut Microbiome Alteration in HIV\/AIDS and the Role of Antiretroviral Therapy-A Scoping Review. Microorganisms, 12.","DOI":"10.37766\/inplasy2024.10.0046"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAD.0000000000003419","article-title":"Gut microbiota alterations after switching from a protease inhibitor or efavirenz to raltegravir in a randomized, controlled study","volume":"37","author":"Hanttu","year":"2023","journal-title":"AIDS"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"21526","DOI":"10.7448\/IAS.20.1.21526","article-title":"Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients","volume":"20","author":"Oteo","year":"2017","journal-title":"J. Int. AIDS Soc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/cid\/ciy716","article-title":"Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy","volume":"68","author":"Moser","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/civ327","article-title":"Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s","volume":"61","author":"Kelesidis","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Narayanan, A., Kieri, O., Vesterbacka, J., Manoharan, L., Chen, P., Ghorbani, M., Ljunggren, H.G., S\u00e4llberg Chen, M., Aleman, S., and S\u00f6nnerborg, A. (2024). Exploring the interplay between antiretroviral therapy and the gut-oral microbiome axis in people living with HIV. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-68479-4"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Roux, C.G., Mason, S., du Toit, L.D.V., Nel, J.G., Rossouw, T.M., and Steel, H.C. (2024). Comparative Effects of Efavirenz and Dolutegravir on Metabolomic and Inflammatory Profiles, and Platelet Activation of People Living with HIV: A Pilot Study. Viruses, 16.","DOI":"10.3390\/v16091462"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00262-023-03608-y","article-title":"Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer","volume":"73","author":"Otsuka","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1099\/ijs.0.65259-0","article-title":"Ruminococcus gauvreauii sp. nov., a glycopeptide-resistant species isolated from a human faecal specimen","volume":"58","author":"Domingo","year":"2008","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref_71","unstructured":"Maheshwari, P., and Murali Sankar, P. (2025, June 27). Microbial Symbionts, Available online: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/B9780323993340000189."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"baaa062","DOI":"10.1093\/database\/baaa062","article-title":"NCBI Taxonomy: A comprehensive update on curation, resources and tools","volume":"2020","author":"Schoch","year":"2020","journal-title":"Database"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1038\/s41467-024-49641-y","article-title":"MiDAS 5: Global diversity of bacteria and archaea in anaerobic digesters","volume":"15","author":"Dueholm","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Martin, R., Rios-Covian, D., Huillet, E., Auger, S., Khazaal, S., Bermudez-Humaran, L.G., Sokol, H., Chatel, J.M., and Langella, P. (2023). Faecalibacterium: A bacterial genus with promising human health applications. FEMS Microbiol. Rev., 47.","DOI":"10.1093\/femsre\/fuad039"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41231-024-00187-7","article-title":"Thiamine deficiency underlies persistent gut dysbiosis and inflammation in people living with HIV on antiretroviral therapy","volume":"9","author":"Ishizaka","year":"2024","journal-title":"Transl. Med. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e00261-19","DOI":"10.1128\/mSystems.00261-19","article-title":"Age- and Sex-Dependent Patterns of Gut Microbial Diversity in Human Adults","volume":"4","author":"Kelley","year":"2019","journal-title":"mSystems"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Badal, V.D., Vaccariello, E.D., Murray, E.R., Yu, K.E., Knight, R., Jeste, D.V., and Nguyen, T.T. (2020). The Gut Microbiome, Aging, and Longevity: A Systematic Review. Nutrients, 12.","DOI":"10.3390\/nu12123759"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/COH.0000000000000611","article-title":"What is the collective effect of aging and HIV on the gut microbiome?","volume":"15","author":"Dillon","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Vacca, M., Celano, G., Calabrese, F.M., Portincasa, P., Gobbetti, M., and De Angelis, M. (2020). The Controversial Role of Human Gut Lachnospiraceae. Microorganisms, 8.","DOI":"10.3390\/microorganisms8040573"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Baltazar-D\u00edaz, T.A., Amador-Lara, F., Andrade-Villanueva, J.F., Gonz\u00e1lez-Hern\u00e1ndez, L.A., Cabrera-Silva, R.I., S\u00e1nchez-Reyes, K., \u00c1lvarez-Zavala, M., Valenzuela-Ram\u00edrez, A., Del Toro-Arreola, S., and Bueno-Topete, M.R. (2023). Gut Bacterial Communities in HIV-Infected Individuals with Metabolic Syndrome: Effects of the Therapy with Integrase Strand Transfer Inhibitor-Based and Protease Inhibitor-Based Regimens. Microorganisms, 11.","DOI":"10.3390\/microorganisms11040951"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Notting, F., Pirovano, W., Sybesma, W., and Kort, R. (2023). The butyrate-producing and spore-forming bacterial genus Coprococcus as a potential biomarker for neurological disorders. Gut Microbiome, 4.","DOI":"10.1017\/gmb.2023.14"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Companys, J., Gosalbes, M.J., Pla-Paga, L., Calderon-Perez, L., Llaurado, E., Pedret, A., Valls, R.M., Jimenez-Hernandez, N., Sandoval-Ramirez, B.A., and Del Bas, J.M. (2021). Gut Microbiota Profile and Its Association with Clinical Variables and Dietary Intake in Overweight\/Obese and Lean Subjects: A Cross-Sectional Study. Nutrients, 13.","DOI":"10.3390\/nu13062032"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Xie, Y., Sun, J., Wei, L., Jiang, H., Hu, C., Yang, J., Huang, Y., Ruan, B., and Zhu, B. (2021). Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals. BMC Microbiol., 21.","DOI":"10.1186\/s12866-020-02074-1"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ebiom.2016.04.033","article-title":"Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals","volume":"8","author":"Rojo","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Crost, E.H., Coletto, E., Bell, A., and Juge, N. (2023). Ruminococcus gnavus: Friend or foe for human health. FEMS Microbiol. Rev., 47.","DOI":"10.1093\/femsre\/fuad014"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10068-024-01631-y","article-title":"The role of Bifidobacterium in longevity and the future of probiotics","volume":"33","author":"Ku","year":"2024","journal-title":"Food Sci. Biotechnol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.csbj.2021.12.006","article-title":"Modeling approaches for probing cross-feeding interactions in the human gut microbiome","volume":"20","author":"Saa","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Martin, A.J.M., Serebrinsky-Duek, K., Riquelme, E., Saa, P.A., and Garrido, D. (2023). Microbial interactions and the homeostasis of the gut microbiome: The role of Bifidobacterium. Microbiome Res. Rep., 2.","DOI":"10.20517\/mrr.2023.10"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/obr.12661","article-title":"Microbiota in obesity: Interactions with enteroendocrine, immune and central nervous systems","volume":"19","author":"Mulders","year":"2018","journal-title":"Obes. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Li, S., Guo, J., Liu, R., Zhang, F., Wen, S., Liu, Y., Ren, W., Zhang, X., Shang, Y., and Gao, M. (2022). Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.01926-22"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/mi.2016.34","article-title":"Bacteroides are associated with GALT iNKT cell function and reduction of microbial translocation in HIV-1 infection","volume":"10","author":"Ching","year":"2017","journal-title":"Mucosal Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Bl\u00e1zquez-Bondia, C., Catal\u00e0-Moll, F., Torres, F., Manzardo, C., Bonfill, E., Falc\u00f3, V., Domingo, P., Podzamczer, D., Force, L., and Curran, A. (2025, June 27). Gut Microbiota Recovery in Late HIV-1 Presenters Initiating First-Line Dolutegravir-Based Antiretroviral Therapy: Results from a 2-Year, Open-Label, Randomized Clinical Trial. Available online: https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=4934503.","DOI":"10.2139\/ssrn.4945213"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Madzime, M., Rossouw, T.M., Theron, A.J., Anderson, R., and Steel, H.C. (2021). Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.634386"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"111217","DOI":"10.1016\/j.mehy.2023.111217","article-title":"3-Hydroxybutyrate could serve as a principal energy substrate for human microbiota","volume":"182","author":"Satoh","year":"2024","journal-title":"Med. Hypotheses"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2567.2003.01636.x","article-title":"The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells","volume":"109","author":"Jones","year":"2003","journal-title":"Immunology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e0081623","DOI":"10.1128\/msphere.00816-23","article-title":"Anaerostipes hadrus, a butyrate-producing bacterium capable of metabolizing 5-fluorouracil","volume":"9","author":"Liu","year":"2024","journal-title":"mSphere"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Lee, J.Y., Kang, W., Shin, N.R., Hyun, D.W., Kim, P.S., Kim, H.S., Lee, J.Y., Tak, E.J., Sung, H., and Bae, J.W. (2021). Anaerostipes hominis sp. nov., a novel butyrate-producing bacteria isolated from faeces of a patient with Crohn\u2019s disease. Int. J. Syst. Evol. Microbiol., 71.","DOI":"10.1099\/ijsem.0.005129"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1099\/ijs.0.007674-0","article-title":"Butyricimonas synergistica gen. nov., sp. nov. and Butyricimonas virosa sp. nov., butyric acid-producing bacteria in the family \u2018Porphyromonadaceae\u2019 isolated from rat faeces","volume":"59","author":"Sakamoto","year":"2009","journal-title":"Int. J. Syst. Evol. Microbiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e00094-18","DOI":"10.1128\/msystems.00094-18","article-title":"Butyrate Producers as Potential Next-Generation Probiotics: Safety Assessment of the Administration of Butyricicoccus pullicaecorum to Healthy Volunteers","volume":"3","author":"Boesmans","year":"2018","journal-title":"mSystems"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3892\/ol.2020.12190","article-title":"A gut butyrate-producing bacterium Butyricicoccus pullicaecorum regulates short-chain fatty acid transporter and receptor to reduce the progression of 1,2-dimethylhydrazine-associated colorectal cancer","volume":"20","author":"Chang","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Lee, H., An, J., Kim, J., Choi, D., Song, Y., Lee, C.K., Kong, H., Kim, S.B., and Kim, K. (2022). A Novel Bacterium, Butyricimonas virosa, Preventing HFD-Induced Diabetes and Metabolic Disorders in Mice via GLP-1 Receptor. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.858192"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Rubio-Garcia, E., Ferrando, N., Martin, N., Ballest\u00e9-Delpierre, C., Mir\u00f3, J.M., Paredes, R., Casals-Pascual, C., and Vila, J. (2023). In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota. Front. Cell Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1306430"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Wallace, V.J., Sakowski, E.G., Preheim, S.P., and Prasse, C. (2023). Bacteria exposed to antiviral drugs develop antibiotic cross-resistance and unique resistance profiles. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-05177-3"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s40121-022-00654-4","article-title":"Integrase Inhibitors Partially Restore Bacterial Translocation, Inflammation and Gut Permeability Induced by HIV Infection: Impact on Gut Microbiota","volume":"11","author":"Metola","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Villoslada-Blanco, P., P\u00e9rez-Matute, P., \u00cd\u00f1iguez, M., Recio-Fern\u00e1ndez, E., Jansen, D., De Coninck, L., Close, L., Blanco-Navarrete, P., Metola, L., and Ibarra, V. (2022). Impact of HIV infection and integrase strand transfer inhibitors-based treatment on the gut virome. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-25979-5"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Armstrong, A.J.S., Shaffer, M., Nusbacher, N.M., Griesmer, C., Fiorillo, S., Schneider, J.M., Preston Neff, C., Li, S.X., Fontenot, A.P., and Campbell, T. (2018). An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men. Microbiome, 6.","DOI":"10.1186\/s40168-018-0580-7"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature18646","article-title":"Human gut microbes impact host serum metabolome and insulin sensitivity","volume":"535","author":"Pedersen","year":"2016","journal-title":"Nature"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jiac.2023.09.013","article-title":"Association between the gut microbiome and organic acid profiles in a Japanese population with HIV infection","volume":"30","author":"Hishiya","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Ling, Z., Jin, C., Xie, T., Cheng, Y., Li, L., and Wu, N. (2016). Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population. Sci. Rep., 6.","DOI":"10.1038\/srep30673"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","article-title":"Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"23","author":"Bajer","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.mayocp.2018.02.019","article-title":"Gut Microbial Carbohydrate Metabolism Hinders Weight Loss in Overweight Adults Undergoing Lifestyle Intervention With a Volumetric Diet","volume":"93","author":"Jensen","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Singh, S.B., Carroll-Portillo, A., and Lin, H.C. (2023). Desulfovibrio in the Gut: The Enemy within?. Microorganisms, 11.","DOI":"10.3390\/microorganisms11071772"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Rizzatti, G., Lopetuso, L.R., Gibiino, G., Binda, C., and Gasbarrini, A. (2017). Proteobacteria: A Common Factor in Human Diseases. Biomed. Res. Int., 2017.","DOI":"10.1155\/2017\/9351507"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1757-4749-5-23","article-title":"Commensal Clostridia: Leading players in the maintenance of gut homeostasis","volume":"5","author":"Lopetuso","year":"2013","journal-title":"Gut Pathog."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Chiu, F.C., Tsai, C.F., Huang, P.S., Shih, C.Y., Tsai, M.H., Hwang, J.J., Wang, Y.C., Chuang, E.Y., Tsai, C.T., and Chang, S.N. (2022). The Gut Microbiome, Seleno-Compounds, and Acute Myocardial Infarction. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051462"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Cui, Y., Zhang, L., Wang, X., Yi, Y., Shan, Y., Liu, B., Zhou, Y., and Lu, X. (2022). Roles of intestinal Parabacteroides in human health and diseases. FEMS Microbiol. Lett., 369.","DOI":"10.1093\/femsle\/fnac072"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1097\/QAD.0b013e32835f2b49","article-title":"Differential penetration of raltegravir throughout gastrointestinal tissue: Implications for eradication and cure","volume":"27","author":"Patterson","year":"2013","journal-title":"AIDS"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"eaap8758","DOI":"10.1126\/scitranslmed.aap8758","article-title":"Heterogeneous antiretroviral drug distribution and HIV\/SHIV detection in the gut of three species","volume":"11","author":"Thompson","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","article-title":"Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment","volume":"210","author":"Tenorio","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e001221","DOI":"10.1161\/JAHA.114.001221","article-title":"A novel protein glycan biomarker and future cardiovascular disease events","volume":"3","author":"Akinkuolie","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection","volume":"210","author":"Hunt","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/10600280211073321","article-title":"Weight Changes With Integrase Strand Transfer Inhibitor Therapy in the Management of HIV Infection: A Systematic Review","volume":"56","author":"Hester","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11904-024-00708-x","article-title":"Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism","volume":"21","author":"Savinelli","year":"2024","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/jiz118","article-title":"Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications","volume":"220","author":"Godfrey","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_126","unstructured":"Pinto-Cardoso, S.M., Ch\u00e1vez-Torres, M., Aguilar, A., and Avila-Rios, S. (2023, January 19\u201322). CHANGES IN GUT MICROBIOTA PROFILE IN PWHIV WHO SWITCH FROM EFV\/FTC\/TDF TO BIC\/FTC\/TAF. Proceedings of the 30th CROI 2023, Seattle, WD, USA."},{"key":"ref_127","first-page":"201027","article-title":"Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution","volume":"2012","author":"Cabezas","year":"2012","journal-title":"Int. J. Vasc. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e13908","DOI":"10.1111\/obr.13908","article-title":"Weight gain, obesity, and the impact of lifestyle factors among people living with HIV: A systematic review","volume":"26","author":"Gilberti","year":"2025","journal-title":"Obes. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2150815","DOI":"10.1080\/25787489.2022.2150815","article-title":"Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV","volume":"24","author":"Guaraldi","year":"2022","journal-title":"HIV Res. Clin. Pract."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","article-title":"Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: A multicentre, prospective observational study from the RESPOND consortium cohorts","volume":"11","author":"Byonanebye","year":"2024","journal-title":"Lancet HIV"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/cid\/ciae406","article-title":"Integrase Strand Transfer Inhibitor-Related Changes in Body Mass Index and Risk of Diabetes: A Prospective Study From the RESPOND Cohort Consortium","volume":"80","author":"Rupasinghe","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"ofad611","DOI":"10.1093\/ofid\/ofad611","article-title":"Changes in Body Mass Index Over Time in People With and Without HIV Infection","volume":"11","author":"Lam","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Muhamad Rizal, N.S., Neoh, H.M., Ramli, R., PR, A.L.K.P., Hanafiah, A., Abdul Samat, M.N., Tan, T.L., Wong, K.K., Nathan, S., and Chieng, S. (2020). Advantages and Limitations of 16S rRNA Next-Generation Sequencing for Pathogen Identification in the Diagnostic Microbiology Laboratory: Perspectives from a Middle-Income Country. Diagnostics, 10.","DOI":"10.3390\/diagnostics10100816"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6366\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:02:49Z","timestamp":1760032969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/13\/6366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":133,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijms26136366"],"URL":"https:\/\/doi.org\/10.3390\/ijms26136366","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}